DT-109 Tripeptide for atherosclerosis

Users discuss DT-109 as a compound that may address plaque, calcification, inflammation, and metabolic issues simultaneously. One notes it is advancing toward human trials based on an AI search and has not appeared on grey markets. Another questions whether a referenced source is legitimate.

• DT-109 is described as potentially reducing plaque, calcification, and inflammation while aiding metabolic and liver health
• It is reported to be in active development and moving into clinical trials
• No sightings yet on grey market sources
• One participant asks if a linked source is legitimate

Whether DT-109 is currently obtainable or legitimate from any source

Nothing here is advice.